Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Verastem Inc (NQ: VSTM )

4.505 -7.675 (-63.01%)
Streaming Delayed Price Updated: 11:48 AM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,533,939
Open 4.690
Bid (Size) 4.500 (20)
Ask (Size) 4.510 (15)
Prev. Close 12.18
Today's Range 4.450 - 5.250
52wk Range 4.932 - 15.18
Shares Outstanding 25,325,551
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is the Stock Market Open on Memorial Day 2024?
Investors wondering if the stock market is open on Memorial Day in 2024 need look no further as we have the answer to that question! 
Via InvestorPlace
7 Things to Know About the Upcoming Nvidia (NVDA) Stock Split
Nvidia is a hot topic among traders on Friday after the company provided investors with details of an NVDA stock split next month. 
Via InvestorPlace

Performance

YTD
-45.72%
-45.72%
1 Month
-53.12%
-53.12%
3 Month
-62.58%
-62.58%
6 Month
-33.46%
-33.46%
1 Year
-15.26%
-15.26%

More News

Read More
NLST Stock Alert: Micron Faces $445 Million Verdict in Netlist Patent Trial
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
Why Is Verastem (VSTM) Stock Down 62% Today?
Via InvestorPlace
Dow Surges 50 Points; US Durable Goods Orders Increase In April
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?
Via Benzinga
Exposures Product Safety
VSTM Stock Earnings: Verastem Beats EPS for Q1 2024
Via InvestorPlace
Recap: Verastem Q4 Earnings
Via Benzinga
Why Ross Stores Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
Verastem Oncology Announces the Initiation of a Rolling Submission of NDA to FDA Seeking Accelerated Approval of Avutometinib and Defactinib Combination for the Treatment of Adult Patients with Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at the RBC Capital Markets Global Healthcare Conference
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Verastem Oncology
Via Business Wire
Global Patient Survey Results Reveal Significant Negative Impact on Social, Emotional and Mental Well-Being for People Living with Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
VSTM Stock Earnings: Verastem Misses EPS for Q4 2023
Via InvestorPlace
Verastem Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Multiple Oral Presentations at SGO 2024 Annual Meeting on Women’s Cancer that Highlight Advances in Low-Grade Serous Ovarian Cancer Research and Reinforce Commitment to Addressing Urgent Unmet Needs
From Verastem Oncology
Via Business Wire
Verastem Oncology Receives Orphan Drug Designation from FDA for Avutometinib Alone or in Combination With Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Preclinical Presentations for New Oral G12D Inhibitor and for Avutometinib and Defactinib Combination as a Backbone of Therapy for RAS/MAPK Driven Cancers at AACR Annual Meeting 2024
From Verastem Oncology
Via Business Wire
Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
3 Stocks That AI Predicts Will Deliver Triple-Digit Returns This Year: February 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.